Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;72(11):e31977.
doi: 10.1002/pbc.31977. Epub 2025 Aug 12.

A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor Patients

Melanie D Degliuomini  1 , Katherine Armstrong  1 , Michael Curry  2 , Audrey Mauguen  3 , Shakeel Modak  4 , Ira J Dunkel  4 , Emily K Slotkin  4 , Gerald A Soff  5 , Jodi V Mones  6 , Michael V Ortiz  4
Affiliations

A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor Patients

Melanie D Degliuomini et al. Pediatr Blood Cancer. 2025 Nov.

Abstract

Chemotherapy-induced thrombocytopenia (CIT) is a common toxicity in patients with cancer, leading to chemotherapy dose reductions and increased platelet transfusions. Although there are well-documented data using thrombopoietin receptor agonists (TPO-RA) in both adult CIT and pediatric immune thrombocytopenia, there is a paucity of data in pediatric CIT. This is a single institutional, retrospective study evaluating the use and safety of romiplostim in pediatric patients with solid tumors undergoing cancer treatment. Romiplostim was well tolerated and appeared to provide clinical benefit. This report advocates for further research using TPO-RA in pediatric patients being treated for cancer.

Keywords: chemotherapy‐induced thrombocytopenia | pediatric oncology | platelet transfusions | thrombopoietin receptor agonists.

PubMed Disclaimer

References

    1. M. D. Degliuomini, K. Armstrong, A. Mauguen, et al., “Chemotherapy‐Induced Thrombocytopenia in Pediatric Oncology: Scope of the Problem and Opportunities for Intervention,” Pediatric Blood & Cancer 69, no. 10 (2022): e29776.
    1. N. Denduluri, D. A. Patt, Y. Wang, et al., “Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices,” Journal of the National Comprehensive Cancer Network: JNCCN 13, no. 11 (2015): 1383–1393.
    1. J. V. Mones and G. Soff, “Management of Thrombocytopenia in Cancer Patients,” Cancer Treatment and Research 179 (2019): 139–150.
    1. R. Parameswaran, M. Lunning, S. Mantha, et al., “Romiplostim for Management of Chemotherapy‐Induced Thrombocytopenia,” Supportive Care in Cancer 22, no. 5 (2014): 1217–1222.
    1. G. A. Soff, Y. Miao, G. Bendheim, et al., “Romiplostim Treatment of Chemotherapy‐Induced Thrombocytopenia,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37, no. 31 (2019): 2892–2898.

LinkOut - more resources